Prespecified secondary analysis of a phase 3 trial in 63 Chinese adults with severe chronic rhinosinusitis with nasal polyps: tezepelumab vs placebo gave numerically greater 52-week falls in nasal-polyp score (LS mean difference -2.03) and nasal congestion score.
Secondary analysisn = 63
Hu et al. Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial